IPNews® – Prescription giant Merck announced today that it lost its recent patent infringement battle against Canadian competitor Apotex.
The Canadian company had been accused of illegally selling a copy of Merck’s popular nasal allergy drug Nasonex. Rather than strictly denying the allegations, Apotex challenged the validity of the Nasonex patent. To continue reading, click: Merck Loses Nasonex Patent Case